In a small proof-of-concept study, measuring changes in 24-hour heart rate indicated with ~90% accuracy whether an individual suffered from depression. Future longitudinal studies with larger sample sizes are needed to further to gain more insight in heart rate as marker for antidepressant treatment approaches.
Dr Carmen Schiweck (Goethe University, Frankfurt) explained: “An innovative study design with the rapid-acting antidepressant ketamine was designed to assess the potential of heart rate or heart rate variability as state marker for depression. We aimed to assess the potential of real-life psychophysiological measures as state markers for depression” [1]. Two innovative elements in this study were the continuous registration of heart rate for several days and nights, as well as the new antidepressant ketamine, which has a fast onset of action. The average resting heart rate may change quite suddenly to reflect the change in mood.
A small sample of patients with major depressive disorder who did not respond to normal treatment (n=16) and healthy controls (n=16) were included in the study. Heart rates were measured for 4 days and 3 nights, after which patients were treated with either ketamine or placebo.
Patients suffering from depression had a higher baseline heart rate (P<0.001; approx. 10-15 beats higher) and a lower heart rate variation compared with healthy controls. After treatment with ketamine, both heart rate and heart rate fluctuation of the patients had changed and become more similar to the controls. Interestingly, the 24-hour heart rate appeared to be an accurate biomarker for depression. Patients were fitted with a wearable mini-ECG that fed the data to an artificial intelligence programme. This programme was able to classify almost 90% of controls and patients correctly as being depressed or not. Dr Schiweck elaborated: “Normally, heart rates are higher during the day and lower during the night. Interestingly, it seems that the drop in heart rate during the night is impaired in depression. This seems to be a way of identifying patients who are at risk to develop depression or to relapse.”
Moreover, patients with a higher resting heart rate responded better to the treatment with ketamine. However, the study was a small proof-of-concept study, and larger studies are needed to further evaluate the role of heart rate as a biomarker for depression.
- Schiweck C, et al. Heart rate and heart rate variability as trait or state marker for depression? Insights from a ketamine treatment paradigm. P.257. ECNP Congress 2020.
Posted on
Previous Article
« Mental health during the COVID-19 pandemic Next Article
Personalised medicine in depression: a realistic way forward? »
« Mental health during the COVID-19 pandemic Next Article
Personalised medicine in depression: a realistic way forward? »
Table of Contents: ECNP 2020
Featured articles
Psychosis and Schizophrenia
Prognostic tools in the management of clinical high risk for psychosis
Reduced auditory cortex activation during speech perception in patients with schizophrenia
Dementia
Predicting MCI and dementia by assessing worrying about memory
Genomics of vascular dementia and stroke
Bipolar Disorders
Social media and bipolar disorder: a risky combination
How to prevent the onset and first relapse of bipolar disorders?
Seasonal pattern and bipolar disorder
OCD and Depression
Personalised medicine in depression: a realistic way forward?
Heart rate could be a potential biomarker for depression
Listening to Mozart has a beneficial effect on epilepsy
Mental Health
Mental health during the COVID-19 pandemic
Microdosing psychedelics offers perspective but needs further evaluation
The PRISM project: focusing on biological parameters across neuropsychiatric disorders
Smartphone can support personalised medicine in psychiatry
Baby’s heart rate shows stress if their mother is depressed or anxious
Autism and ADHD
Movement computing promising in analysing motor impairment in children with autism spectrum disorder
Screening with ADHD Self-Report accurate in girls
No altered fractional anisotropy in ADHD
Role of the Microbiome
Micronutrient supplementation as treatment for psychiatric symptoms
Substance Abuse
Altered gene expression of endogenous opioid system after alcohol exposure in adolescent rodents
Subgroups in alcohol use disorder based on externalising symptoms
New drugs for alcohol use disorder to focus on combination therapy
Related Articles

November 2, 2020
ECNP 2020 Highlights Podcast
November 26, 2021
Connecting, challenging, and empowering youth through their smartphone
November 28, 2022
Zuranolone shows rapid-acting efficacy in postpartum depression
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com